MetaCap

Design Therapeutics (DSGN) vs Janux Therapeutics (JANX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Design Therapeutics (DSGN) has outperformed Janux Therapeutics (JANX) over the past year, gaining 8.0% versus a loss of 65.0%. Over five years, JANX leads with a -42.9% price change compared with -49.3% for DSGN. Janux Therapeutics is the larger company by market cap ($616.7 million vs $577.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DSGN+8.02%JANX-65.00%
+99%+13%-73%
Nov 21, 20251 yearNov 20, 2026
DSGN-56.02%JANX-43.62%
+281%+87%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DSGN versus JANX key metrics
MetricDSGNJANX
Share price$9.02$10.08
Market cap$577.61M$616.73M
1-day change-3.22%-2.04%
YTD return-3.84%-26.96%
1-year return+8.02%-65.00%
5-year return-49.27%-42.92%
EPS (TTM)$-1.20$-1.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$10.00M
Revenue growth (YoY)—-5.55%
Net income (latest FY)$-69.79M$-113.63M
Operating margin—-1576.67%
Net margin—-1136.25%
52-week high$17.25$35.34
52-week low$8.21$10.05
Distance from 52-week high-47.71%-71.48%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+139.14%+228.77%
Average volume554.69K961.56K
Shares outstanding64.04M61.18M
Employees60114
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DSGN has outperformed JANX by 73.0 percentage points over the past year.

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

DSGN vs JANX FAQ

Which is bigger, Design Therapeutics or Janux Therapeutics?

Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $577.61M for Design Therapeutics (DSGN).

Which stock has performed better over the past year, DSGN or JANX?

DSGN returned +8.02% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Design Therapeutics and Janux Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons